Matinas' MAT2203 meets in Phase IIa for mucocutaneous candidiasis

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported data from three evaluable patients with chronic refractory mucocutaneous candidiasis in a Phase IIa trial showing that oral MAT2203 (CAmB) met the primary endpoint of reducing clinical symptoms. To meet the endpoint, the trial protocol required three out of 16 patients to achieve a ≥50% reduction in clinical symptoms. The first three patients enrolled in the trial achieved the endpoint, with the first two patients achieving reductions in clinical symptoms of 57% and 85%, respectively. MAT2203 was generally well tolerated.

Secondary endpoints in the open-label, U.S. trial include safety and pharmacokinetics...